您的购物车当前为空
STAT3-IN-12 是一种强效 STAT3 信号抑制剂,可抑制 IL-6 诱导的 JAK/STAT3 通路激活。该化合物能抑制癌细胞增殖、迁移,并诱导凋亡及细胞周期阻滞,适用于肝细胞癌(HCC)和食管癌等研究。


为众多的药物研发团队赋能,
让新药发现更简单!
STAT3-IN-12 是一种强效 STAT3 信号抑制剂,可抑制 IL-6 诱导的 JAK/STAT3 通路激活。该化合物能抑制癌细胞增殖、迁移,并诱导凋亡及细胞周期阻滞,适用于肝细胞癌(HCC)和食管癌等研究。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 563 | In stock | |
| 5 mg | ¥ 1,230 | In stock | |
| 10 mg | ¥ 1,980 | In stock | |
| 25 mg | ¥ 3,830 | In stock | |
| 50 mg | ¥ 5,520 | In stock | |
| 100 mg | ¥ 8,620 | In stock | |
| 200 mg | ¥ 11,600 | In stock |
STAT3-IN-12 相关产品
| 产品描述 | STAT3-IN-12, a potent STAT3 signaling inhibitor, suppresses IL-6-induced JAK/STAT3 pathway activation. This compound inhibits cancer cell proliferation and migration while inducing apoptosis and cell cycle arrest, making it suitable for hepatocellular carcinoma (HCC) and esophageal cancer research. |
| 靶点活性 | EC109 cells:3.63 μM, HepG2 cells:4.32 μM |
| 体外活性 | 方法:STAT3-IN-12 (0,1.25,2.5,5,10μM,16-72小时)处理HepG2 和 EC109 细胞,进行细胞活力测定、细胞迁移测定和WB检测。 |
| 体内活性 | 方法:STAT3-IN-12(20,40mg/kg腹腔注射,每天,24天)处理HepG2细胞异种移植肿瘤模型小鼠,研究其对小鼠体内肿瘤生长的影响作用。 |
| 分子量 | 454.56 |
| 分子式 | C28H30N4O2 |
| CAS No. | 2980758-31-2 |
| Smiles | N=1C=2C=C3N=C(C=4C=CC=C(OC)C4)N(C3=CC2N(C1C=5C=CC=C(OC)C5)CCC)CCC |
| 密度 | no data available |
| 颜色 | Brown |
| 物理性状 | Solid |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 80 mg/mL (175.99 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容